Saisheng Pharmaceutical (06600): 10,000 share options have been exercised
Saisheng Pharmaceutical (06600) issued an announcement. On April 30, 2024, according to the initial public offering after-sales share purchase options...
華潤醫藥:公告有關於中國發行中期票據及公司債券的華潤醫藥控股截至2024年3月31日止三個月的未經審核財務業績
China Holdings Kangtai (01312.HK) denies the charges in the 2024 Cayman petition
Gelonghui, April 30 | Huakong Kangtai (01312.HK) issued an announcement. As of the date of this announcement, neither the 2019 Hong Kong legal proceedings nor the 2021 Hong Kong legal proceedings had been tried. On April 29, 2024, the company received a petition from Active Gains (as petitioner) from True Cayman and Fester Global's overseas registered agents against True Cayman dated April 25, 2024, with respect to: (a) liquidation of True Cayman; (b)
Hansoh Pharmaceutical's 2023 Profit Up 27%
Hansoh Pharmaceutical Group (HKG:3692) recorded a 27% rise in attributable profit for 2023 to 3.28 billion yuan from 2.58 billion yuan in 2022, according to the company's annual report. Earnings per s
Xiansheng Pharmaceutical (02096.HK) spent HK$1,457,800 to repurchase 270,000 shares on April 30
Gelonghui, April 30 | Xiansheng Pharmaceutical (02096.HK) announced that it spent HK$1.457,800 to repurchase 270,000 shares on April 30.
Cinda Biotech (01801.HK): Total product revenue in the first quarter exceeded 1.7 billion yuan, a strong year-on-year increase of more than 60%
On April 30, Gelonghui | Cinda Biotech (01801.HK) announced that in the first quarter of 2024, the company achieved total product revenue exceeding RMB 1.7 billion, a strong increase of over 60% over the previous year. The overall product portfolio continued to grow rapidly during the quarter, thanks to advantages such as broad indication potential, health insurance coverage and complete access channels. Dabershu (Cindilizumab Injection) continues to achieve strong sales performance and a stable market leading position. Other products have also grown significantly. In particular, new products have accelerated growth and continued to increase their contribution.